Astrazeneca

IMJUDO

Manufacturer:

Astrazeneca

Imjudo HCPCS:

C9147

HCPCS Code Descriptor:

Injection, tremelimumab-actl, 1 mg

Category:

C Code

Imjudo NDCs:

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Imjudo:

IMJUDO is an Oncology drug manufactured by Astrazeneca and administered via the Intravenous route of administration. The C Code: C9147 is aligned to the drug IMJUDO.

ACCESS PRICING AND MORE BY REGISTERING

C9147 Added Date:

April 1, 2023

C9147 Effective Date:

July 1, 2023

C9147 Termination Date:

June 30, 2023

We have not yet identified a manufacturer source of Imjudo billing and coding information.
Imjudo patient assistance information can be found through The AZ&Me Prescription Savings Program at the URL: https://www.azandmeapp.com/prescriptionsavings/
IMJUDO prescribing information can be found at the link below:
Information regarding IMJUDO’s side effects can be found at MedlinePlus